
    
      evaluate the progression-free survival(PFS) and also survival of IP and EP (head-to-head) as
      the first line therapy for extensive stage small-cell lung cancer and to explore the
      reasonable first-line therapy for Chinese population.

      An open-label, multi-center study will be conducted with dynamic randomization of
      approximately 1:1 ratio with an estimation of 308 eligible participants.
    
  